Search results
Results from the WOW.Com Content Network
Pregnancy-induced hypercoagulability is probably a physiologically adaptive mechanism to prevent post partum hemorrhage. [1] Pregnancy changes the plasma levels of many clotting factors, such as fibrinogen, which can rise up to three times its normal value. [2] Thrombin levels increase. [3] Protein S, an anticoagulant, decreases.
An antihemorrhagic (British English: antihaemorrhagic) agent is a substance that promotes hemostasis (a process which stops bleeding). [1] It may also be known as a hemostatic (also spelled haemostatic) agent.
An anticoagulant, commonly known as a blood thinner, is a chemical substance that prevents or reduces the coagulation of blood, prolonging the clotting time. [1] Some occur naturally in blood-eating animals, such as leeches and mosquitoes, which help keep the bite area unclotted long enough for the animal to obtain blood.
Coagulation, also known as clotting, is the process by which blood changes from a liquid to a gel, forming a blood clot.It results in hemostasis, the cessation of blood loss from a damaged vessel, followed by repair.
Women should speak to their doctor or healthcare professional before starting or stopping any medications while pregnant. [1] Drugs taken in pregnancy including over-the counter-medications, prescription medications, nutritional supplements, recreational drugs, and illicit drugs may cause harm to the mother or the unborn child.
The partial thromboplastin time (PTT), also known as the activated partial thromboplastin time (aPTT or APTT), is a blood test that characterizes coagulation of the blood.A historical name for this measure is the Kaolin-cephalin clotting time (KCCT), [1] reflecting kaolin and cephalin as materials historically used in the test.
Eltrombopag, sold under the brand name Promacta among others, is a medication used to treat thrombocytopenia (abnormally low platelet counts) and severe aplastic anemia. [3] [4] Eltrombopag is sold under the brand name Revolade outside the US and is marketed by Novartis. [6]
[2] [3] [4] It was the first product for use in menopausal hormone therapy containing CPA to be marketed [3] and is available in more than 40 countries. [2] Femilar, which is an estradiol-containing birth control pill , contains 1 to 2 mg estradiol valerate and 1 to 2 mg CPA, and has been approved for use in Finland since 1993.